Mangoceuticals, Inc.

MGRX Nasdaq SEC CIK 1938046
Follow Mangoceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $69.5K −17.5% vs same quarter last year
Net income −$3.6M +53.4% vs same quarter last year
EPS, diluted −$0.19 +72.5% vs same quarter last year
Operating cash flow −$1.1M +7.4% vs same quarter last year
Revenue by quarter
$105.2K
$109.3K
$168.1K
$84.2K
$94.4K
$67.9K
$68.8K
$69.5K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0$10MFY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$456K−$20.6M
FY24$615.9K−$8.7M
FY23$731.5K−$9.2M
FY22$8.9K−$2M
FY21--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−30000%−20000%−10000%0%10000%FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2554.9%−3954.3%−4526.8%
FY2461.7%−1294.4%−1413.6%
FY2359%−1260.3%−1259.4%
FY2254.3%−22279.7%−22352.1%
FY21---
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Mangoceuticals
  • Healthcare median
−30000%−20000%−10000%0%FY21FY22FY23FY24FY25
Show the numbers
YearMangoceuticalsHealthcare median
FY25−4526.8%−30.6%
FY24−1413.6%−47%
FY23−1259.4%−58%
FY22−22352.1%−80.4%
FY21-−71.9%